Compile Data Set for Download or QSAR

Found 302 hits Enz. Inhib. hit(s) with all data for entry = 9083   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Plasma kallikrein (Homo sapiens (Human))	BDBM416879 (1-(3-(aminomethyl)phenyl)-N-(3-((3-cyanophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc(c1)C#N)C(F)(F)F Show InChI InChI=1S/C30H27F3N6O/c31-30(32,33)27-15-26(39(38-27)25-9-2-5-21(13-25)17-35)29(40)37-24-8-3-7-23(14-24)28(36-18-19-10-11-19)22-6-1-4-20(12-22)16-34/h1-9,12-15,19,28,36H,10-11,17-18,35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416882 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) Show SMILES COc1ccc(C(NCC2CC2)c2cccc(NC(=O)c3cc(nn3-c3cccc(CN)c3)C(F)(F)F)c2)c2ccccc12 Show InChI InChI=1S/C34H32F3N5O2/c1-44-30-15-14-28(26-10-2-3-11-27(26)30)32(39-20-21-12-13-21)23-7-5-8-24(17-23)40-33(43)29-18-31(34(35,36)37)41-42(29)25-9-4-6-22(16-25)19-38/h2-11,14-18,21,32,39H,12-13,19-20,38H2,1H3,(H,40,43)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416884 (1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES Cc1ccccc1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C30H30F3N5O/c1-19-6-2-3-11-25(19)28(35-18-20-12-13-20)22-8-5-9-23(15-22)36-29(39)26-16-27(30(31,32)33)37-38(26)24-10-4-7-21(14-24)17-34/h2-11,14-16,20,28,35H,12-13,17-18,34H2,1H3,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416885 (1-(3-(aminomethyl)phenyl)-N-(5-((3-(aminomethyl)ph...) Show SMILES NCc1cccc(c1)C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C30H30F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,15-17,35-36H2,(H,38,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416888 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-me...) Show SMILES COC(CCC1CC1)(c1cccnc1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C30H30F3N5O2/c1-40-29(13-12-20-10-11-20,23-7-4-14-35-19-23)22-6-3-8-24(16-22)36-28(39)26-17-27(30(31,32)33)37-38(26)25-9-2-5-21(15-25)18-34/h2-9,14-17,19-20H,10-13,18,34H2,1H3,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416890 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc(F)c1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O/c30-22-7-2-5-20(13-22)27(35-17-18-10-11-18)21-6-3-8-23(14-21)36-28(39)25-15-26(29(31,32)33)37-38(25)24-9-1-4-19(12-24)16-34/h1-9,12-15,18,27,35H,10-11,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM439471 (US10633345, Compound 54e | US10633345, Compound 70...) Show SMILES CN(C(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1 Show InChI InChI=1S/C30H26F4N6O/c1-39(22-9-10-22)28(20-6-2-4-18(12-20)16-35)21-8-11-24(31)25(14-21)37-29(41)26-15-27(30(32,33)34)38-40(26)23-7-3-5-19(13-23)17-36/h2-8,11-15,22,28H,9-10,17,36H2,1H3,(H,37,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416893 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(F)cc1F)C(F)(F)F Show InChI InChI=1S/C29H26F5N5O/c30-20-9-10-23(24(31)13-20)27(36-16-17-7-8-17)19-4-2-5-21(12-19)37-28(40)25-14-26(29(32,33)34)38-39(25)22-6-1-3-18(11-22)15-35/h1-6,9-14,17,27,36H,7-8,15-16,35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416894 (1-(3-(aminomethyl)phenyl)-N-(5-((4-cyanophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1ccc(cc1)C#N)C(F)(F)F Show InChI InChI=1S/C30H25F4N5O2/c31-24-11-10-22(28(41-17-19-4-5-19)21-8-6-18(15-35)7-9-21)13-25(24)37-29(40)26-14-27(30(32,33)34)38-39(26)23-3-1-2-20(12-23)16-36/h1-3,6-14,19,28H,4-5,16-17,36H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416896 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cc(F)ccc1F)C(F)(F)F Show InChI InChI=1S/C29H26F5N5O/c30-20-9-10-24(31)23(13-20)27(36-16-17-7-8-17)19-4-2-5-21(12-19)37-28(40)25-14-26(29(32,33)34)38-39(25)22-6-1-3-18(11-22)15-35/h1-6,9-14,17,27,36H,7-8,15-16,35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416897 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-23-9-8-20(28(40,11-10-18-6-7-18)21-4-2-12-35-17-21)14-24(23)36-27(39)25-15-26(29(31,32)33)37-38(25)22-5-1-3-19(13-22)16-34/h1-5,8-9,12-15,17-18,40H,6-7,10-11,16,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416899 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1c(F)cccc1F)C(F)(F)F Show InChI InChI=1S/C29H26F5N5O/c30-22-8-3-9-23(31)26(22)27(36-16-17-10-11-17)19-5-2-6-20(13-19)37-28(40)24-14-25(29(32,33)34)38-39(24)21-7-1-4-18(12-21)15-35/h1-9,12-14,17,27,36H,10-11,15-16,35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416900 (1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccc(c1)C#N)C(F)(F)F Show InChI InChI=1S/C30H25F4N5O2/c31-24-10-9-22(28(41-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)37-29(40)26-14-27(30(32,33)34)38-39(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28H,7-8,16-17,36H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416902 (1-(3-(aminomethyl)phenyl)-N-(3-((2-chlorophenyl)((...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1Cl)C(F)(F)F Show InChI InChI=1S/C29H27ClF3N5O/c30-24-10-2-1-9-23(24)27(35-17-18-11-12-18)20-6-4-7-21(14-20)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-3-5-19(13-22)16-34/h1-10,13-15,18,27,35H,11-12,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416903 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H28F4N4O2/c31-24-12-11-22(29(40,14-13-19-9-10-19)21-6-2-1-3-7-21)16-25(24)36-28(39)26-17-27(30(32,33)34)37-38(26)23-8-4-5-20(15-23)18-35/h1-8,11-12,15-17,19,40H,9-10,13-14,18,35H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416902 (1-(3-(aminomethyl)phenyl)-N-(3-((2-chlorophenyl)((...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1Cl)C(F)(F)F Show InChI InChI=1S/C29H27ClF3N5O/c30-24-10-2-1-9-23(24)27(35-17-18-11-12-18)20-6-4-7-21(14-20)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-3-5-19(13-22)16-34/h1-10,13-15,18,27,35H,11-12,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416906 (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C34H31F4N5O2/c1-45-29-14-12-22-6-2-3-8-25(22)31(29)32(40-19-20-9-10-20)23-11-13-26(35)27(16-23)41-33(44)28-17-30(34(36,37)38)42-43(28)24-7-4-5-21(15-24)18-39/h2-8,11-17,20,32,40H,9-10,18-19,39H2,1H3,(H,41,44)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416908 (1-(3-(aminomethyl)phenyl)-N-(3-((2,4-dichloropheny...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(Cl)cc1Cl)C(F)(F)F Show InChI InChI=1S/C29H26Cl2F3N5O/c30-20-9-10-23(24(31)13-20)27(36-16-17-7-8-17)19-4-2-5-21(12-19)37-28(40)25-14-26(29(32,33)34)38-39(25)22-6-1-3-18(11-22)15-35/h1-6,9-14,17,27,36H,7-8,15-16,35H2,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416909 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-22-10-9-20(28(40,12-11-18-7-8-18)25-6-1-2-13-35-25)15-23(22)36-27(39)24-16-26(29(31,32)33)37-38(24)21-5-3-4-19(14-21)17-34/h1-6,9-10,13-16,18,40H,7-8,11-12,17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM439493 (US10633345, Compound 201f) Show SMILES Cc1ccc(C(NCCC2CC2)c2cccc(NC(=O)c3cc(nn3-c3cccc(CN)c3)C(F)(F)F)c2)c(C)c1 Show InChI InChI=1S/C32H34F3N5O/c1-20-9-12-27(21(2)15-20)30(37-14-13-22-10-11-22)24-6-4-7-25(17-24)38-31(41)28-18-29(32(33,34)35)39-40(28)26-8-3-5-23(16-26)19-36/h3-9,12,15-18,22,30,37H,10-11,13-14,19,36H2,1-2H3,(H,38,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416912 (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) Show SMILES Cc1ccc(C)c(c1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C31H32F3N5O/c1-19-9-10-20(2)26(13-19)29(36-18-21-11-12-21)23-6-4-7-24(15-23)37-30(40)27-16-28(31(32,33)34)38-39(27)25-8-3-5-22(14-25)17-35/h3-10,13-16,21,29,36H,11-12,17-18,35H2,1-2H3,(H,37,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416775 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H27F3N4O2/c30-29(31,32)26-16-25(36(35-26)24-11-4-6-20(14-24)17-33)28(37)34-23-10-5-9-22(15-23)27(38-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27H,12-13,17-18,33H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416773 (1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O/c30-23-12-11-21(27(35-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27,35H,9-10,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416775 (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H27F3N4O2/c30-29(31,32)26-16-25(36(35-26)24-11-4-6-20(14-24)17-33)28(37)34-23-10-5-9-22(15-23)27(38-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27H,12-13,17-18,33H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416773 (1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O/c30-23-12-11-21(27(35-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27,35H,9-10,16-17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416843 (1-(3-(aminomethyl)phenyl)-N-(3-((4-aminophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(N)cc1)C(F)(F)F Show InChI InChI=1S/C29H29F3N6O/c30-29(31,32)26-15-25(38(37-26)24-6-1-3-19(13-24)16-33)28(39)36-23-5-2-4-21(14-23)27(35-17-18-7-8-18)20-9-11-22(34)12-10-20/h1-6,9-15,18,27,35H,7-8,16-17,33-34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416897 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-23-9-8-20(28(40,11-10-18-6-7-18)21-4-2-12-35-17-21)14-24(23)36-27(39)25-15-26(29(31,32)33)37-38(25)22-5-1-3-19(13-22)16-34/h1-5,8-9,12-15,17-18,40H,6-7,10-11,16,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416843 (1-(3-(aminomethyl)phenyl)-N-(3-((4-aminophenyl)(cy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(N)cc1)C(F)(F)F Show InChI InChI=1S/C29H29F3N6O/c30-29(31,32)26-15-25(38(37-26)24-6-1-3-19(13-24)16-33)28(39)36-23-5-2-4-21(14-23)27(35-17-18-7-8-18)20-9-11-22(34)12-10-20/h1-6,9-15,18,27,35H,7-8,16-17,33-34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416897 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-23-9-8-20(28(40,11-10-18-6-7-18)21-4-2-12-35-17-21)14-24(23)36-27(39)25-15-26(29(31,32)33)37-38(25)22-5-1-3-19(13-22)16-34/h1-5,8-9,12-15,17-18,40H,6-7,10-11,16,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416721 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-15-24(36(35-25)22-8-3-5-19(13-22)16-32)27(37)34-21-7-4-6-20(14-21)26(38-17-18-10-11-18)23-9-1-2-12-33-23/h1-9,12-15,18,26H,10-11,16-17,32H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM439471 (US10633345, Compound 54e | US10633345, Compound 70...) Show SMILES CN(C(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1 Show InChI InChI=1S/C30H26F4N6O/c1-39(22-9-10-22)28(20-6-2-4-18(12-20)16-35)21-8-11-24(31)25(14-21)37-29(41)26-15-27(30(32,33)34)38-40(26)23-7-3-5-19(13-23)17-36/h2-8,11-15,22,28H,9-10,17,36H2,1H3,(H,37,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416721 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-15-24(36(35-25)22-8-3-5-19(13-22)16-32)27(37)34-21-7-4-6-20(14-21)26(38-17-18-10-11-18)23-9-1-2-12-33-23/h1-9,12-15,18,26H,10-11,16-17,32H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM439471 (US10633345, Compound 54e | US10633345, Compound 70...) Show SMILES CN(C(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1 Show InChI InChI=1S/C30H26F4N6O/c1-39(22-9-10-22)28(20-6-2-4-18(12-20)16-35)21-8-11-24(31)25(14-21)37-29(41)26-15-27(30(32,33)34)38-40(26)23-7-3-5-19(13-23)17-36/h2-8,11-15,22,28H,9-10,17,36H2,1H3,(H,37,41)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416930 (1-(3-(Aminomethyl)phenyl)-N-(3-((3-bromo-4-hydroxy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(O)c(Br)c1)C(F)(F)F Show InChI InChI=1S/C29H27BrF3N5O2/c30-23-13-20(9-10-25(23)39)27(35-16-17-7-8-17)19-4-2-5-21(12-19)36-28(40)24-14-26(29(31,32)33)37-38(24)22-6-1-3-18(11-22)15-34/h1-6,9-14,17,27,35,39H,7-8,15-16,34H2,(H,36,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416725 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-14-24(36(35-25)23-8-1-4-19(12-23)15-32)27(37)34-22-7-2-5-20(13-22)26(38-17-18-9-10-18)21-6-3-11-33-16-21/h1-8,11-14,16,18,26H,9-10,15,17,32H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416909 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-22-10-9-20(28(40,12-11-18-7-8-18)25-6-1-2-13-35-25)15-23(22)36-27(39)24-16-26(29(31,32)33)37-38(24)21-5-3-4-19(14-21)17-34/h1-6,9-10,13-16,18,40H,7-8,11-12,17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416933 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(2...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(CCC1CC1)n1ccccc1=O)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-17-25(37(35-26)23-8-3-5-20(15-23)18-33)28(39)34-22-7-4-6-21(16-22)24(13-12-19-10-11-19)36-14-2-1-9-27(36)38/h1-9,14-17,19,24H,10-13,18,33H2,(H,34,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416725 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-14-24(36(35-25)23-8-1-4-19(12-23)15-32)27(37)34-22-7-2-5-20(13-22)26(38-17-18-9-10-18)21-6-3-11-33-16-21/h1-8,11-14,16,18,26H,9-10,15,17,32H2,(H,34,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416909 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccn1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-22-10-9-20(28(40,12-11-18-7-8-18)25-6-1-2-13-35-25)15-23(22)36-27(39)24-16-26(29(31,32)33)37-38(24)21-5-3-4-19(14-21)17-34/h1-6,9-10,13-16,18,40H,7-8,11-12,17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416936 (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(2...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(CCC1CC1)N1CCCC1=O)C(F)(F)F Show InChI InChI=1S/C28H30F3N5O2/c29-28(30,31)25-16-24(36(34-25)22-7-1-4-19(14-22)17-32)27(38)33-21-6-2-5-20(15-21)23(12-11-18-9-10-18)35-13-3-8-26(35)37/h1-2,4-7,14-16,18,23H,3,8-13,17,32H2,(H,33,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416770 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-16-25(37(36-26)24-8-1-4-20(14-24)17-33)27(38)35-23-7-2-5-21(15-23)28(39,12-11-19-9-10-19)22-6-3-13-34-18-22/h1-8,13-16,18-19,39H,9-12,17,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416903 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H28F4N4O2/c31-24-12-11-22(29(40,14-13-19-9-10-19)21-6-2-1-3-7-21)16-25(24)36-28(39)26-17-27(30(32,33)34)37-38(26)23-8-4-5-20(15-23)18-35/h1-8,11-12,15-17,19,40H,9-10,13-14,18,35H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416939 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccccc1=O)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-20(24(12-9-18-7-8-18)37-13-2-1-6-27(37)39)15-23(22)35-28(40)25-16-26(29(31,32)33)36-38(25)21-5-3-4-19(14-21)17-34/h1-6,10-11,13-16,18,24H,7-9,12,17,34H2,(H,35,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416770 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-16-25(37(36-26)24-8-1-4-20(14-24)17-33)27(38)35-23-7-2-5-21(15-23)28(39,12-11-19-9-10-19)22-6-3-13-34-18-22/h1-8,13-16,18-19,39H,9-12,17,33H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416903 (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H28F4N4O2/c31-24-12-11-22(29(40,14-13-19-9-10-19)21-6-2-1-3-7-21)16-25(24)36-28(39)26-17-27(30(32,33)34)37-38(26)23-8-4-5-20(15-23)18-35/h1-8,11-12,15-17,19,40H,9-10,13-14,18,35H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416942 (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccncc1=O)C(F)(F)F Show InChI InChI=1S/C28H26F4N6O2/c29-21-8-7-19(23(9-6-17-4-5-17)37-11-10-34-16-26(37)39)13-22(21)35-27(40)24-14-25(28(30,31)32)36-38(24)20-3-1-2-18(12-20)15-33/h1-3,7-8,10-14,16-17,23H,4-6,9,15,33H2,(H,35,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416751 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H29F3N4O2/c31-30(32,33)27-18-26(37(36-27)25-11-4-6-21(16-25)19-34)28(38)35-24-10-5-9-23(17-24)29(39,15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,39H,12-15,19,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416906 (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1 Show InChI InChI=1S/C34H31F4N5O2/c1-45-29-14-12-22-6-2-3-8-25(22)31(29)32(40-19-20-9-10-20)23-11-13-26(35)27(16-23)41-33(44)28-17-30(34(36,37)38)42-43(28)24-7-4-5-21(15-24)18-39/h2-8,11-17,20,32,40H,9-10,18-19,39H2,1H3,(H,41,44)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416945 (US10329260, Compound 250c | US10633345, Compound 2...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)Oc1ccccn1)C(F)(F)F Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-20(25(12-9-18-7-8-18)40-27-6-1-2-13-35-27)15-23(22)36-28(39)24-16-26(29(31,32)33)37-38(24)21-5-3-4-19(14-21)17-34/h1-6,10-11,13-16,18,25H,7-9,12,17,34H2,(H,36,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM416751 (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F Show InChI InChI=1S/C30H29F3N4O2/c31-30(32,33)27-18-26(37(36-27)25-11-4-6-21(16-25)19-34)28(38)35-24-10-5-9-23(17-24)29(39,15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,39H,12-15,19,34H2,(H,35,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	25.1	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				US Patent US10633345 (2020) BindingDB Entry DOI: 10.7270/Q26Q218G
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 302 total )  |  Next  |  Last  >>

Jump to: